Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) news covers a commercial-stage pharmaceuticals company focused on plant-based prescription medicines for gastrointestinal distress in humans and animals. The company’s updates frequently highlight progress across its crofelemer programs, regulatory interactions, and partnerships.
Investors following JAGX news can expect coverage of developments related to Mytesi, Napo Pharmaceuticals’ FDA-approved crofelemer product for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, as well as Jaguar’s broader intestinal failure program targeting rare disorders such as short bowel syndrome with intestinal failure (SBS-IF) and microvillus inclusion disease (MVID). News items often describe clinical trial milestones, proof-of-concept data on reductions in parenteral support, and discussions with regulators about potential expedited approval pathways for ultrarare pediatric indications.
On the animal health side, Jaguar news includes information about Canalevia-CA1, the company’s conditionally approved crofelemer-based prescription drug for chemotherapy-induced diarrhea in dogs, along with regulatory grants, conditional approval renewals, and studies designed to support full approval. Updates may also address efforts to obtain guidance from the European Medicines Agency for Canalevia in general diarrhea in dogs.
Corporate and capital markets announcements are another key component of JAGX news. These can include securities purchase agreements, royalty interest amendments, PIPE financings, preferred stock exchanges, and at-the-market offering amendments, as disclosed in Form 8-K filings. Conference presentations, investor summit appearances, and summaries of stockholder meeting results also appear in the company’s news flow.
For investors and observers, the Jaguar Health news page provides a centralized view of clinical, regulatory, commercial, and financing developments that shape the company’s strategy in plant-based gastrointestinal therapeutics for both human and veterinary medicine.
Jaguar Health (NASDAQ:JAGX) announced plans to pursue European Medicines Agency approval for Canalevia to treat general diarrhea in dogs in the EU. The drug, which contains plant-based crofelemer, is currently conditionally FDA-approved for chemotherapy-induced diarrhea in dogs under the name Canalevia-CA1.
The company is in discussions with potential animal health partners to achieve three goals: EU approval for general diarrhea treatment, maintaining U.S. availability for chemotherapy-induced diarrhea, and expanding U.S. indication to include general diarrhea. A completed study of 200 dogs showed significant improvement in fecal scores using a revised endpoint analysis. The potential market is substantial, with 104 million dogs in Europe and approximately 6 million annual cases of acute and chronic diarrhea in U.S. veterinary practices.
Jaguar Health (NASDAQ:JAGX) has announced the extension of maturity date for its convertible promissory notes from June 30, 2025 to January 30, 2026. The extension applies to approximately $2.57 million in aggregate principal amount from the original $3.448 million bridge financing that closed on March 31, 2025. Prior to this extension, five investors converted $0.866 million (including accrued interest) into company equity.
The bridge financing participants include the company's CEO, board members, other C-suite executives, and institutional and accredited investors. The funding aims to support Jaguar's three core development programs for crofelemer: orphan disease intestinal failure program, cancer therapy-related diarrhea treatment, and expansion of Canalevia® for dogs.
Jaguar Health (NASDAQ:JAGX) has announced a $1.5 million registered direct offering priced at-the-market. The company will sell 246,306 shares of common stock at $6.09 per share. Additionally, in a concurrent private placement, Jaguar will issue unregistered warrants to purchase up to 492,612 shares at an exercise price of $5.84 per share, exercisable immediately and expiring within 24 months.
H.C. Wainwright & Co. serves as the exclusive placement agent. The offering is expected to close around May 22, 2025. Jaguar plans to use the net proceeds for general corporate purposes, including growth capital, working capital, operating expenses, repayment of outstanding convertible promissory notes, and capital expenditures.
FAQ
What is the current stock price of Jaguar Health (JAGX)?
What is the market cap of Jaguar Health (JAGX)?
